Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body ...

Vikrant Shrotriya, Corporate Vice President Managing Director of Novo Nordisk India, during a session on India Today Conclave ...

The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...

Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative ...

GLP-1 medications have become a popular weight loss method, but what do Americans really think about them? To find out, we surveyed U.S. adults on their experiences.

A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide—also known as ...